Botanix Pharmaceuticals Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
BOT
- Investments
-
2
- Share Price
-
$0.25
- (As of Friday Closing)
Botanix Pharmaceuticals General Information
Description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
Contact Information
Website
www.botanixpharma.comCorporate Office
- 41 - 47 Colin Street
- Suite 3
- West Perth, Western Australia 6005
- Australia
Corporate Office
- 41 - 47 Colin Street
- Suite 3
- West Perth, Western Australia 6005
- Australia
Botanix Pharmaceuticals Timeline
Botanix Pharmaceuticals Stock Performance
As of 16-May-2025, Botanix Pharmaceuticals’s stock price is $0.25. Its current market cap is $482M with 1.95B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.24 | $0.18 - $0.34 | $482M | 1.95B | 10.4M |
Botanix Pharmaceuticals Financials Summary
As of 31-Mar-2025, Botanix Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 494,280 | 348,916 | 106,154 | 33,230 |
| Revenue | 394 | 69 | ||
| EBITDA | (9,084) | (6,069) | (9,440) | |
| Net Income | (9,089) | (6,154) | (9,544) | |
| Total Assets | 75,171 | 16,440 | 9,656 | |
| Total Debt | 0 | 0 | 84 |
Botanix Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Botanix Pharmaceuticals Comparisons
Industry
Financing
Details
Botanix Pharmaceuticals Competitors (48)
One of Botanix Pharmaceuticals’s 48 competitors is Clinuvel Pharmaceuticals, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Clinuvel Pharmaceuticals | Corporation | Melbourne, Australia | ||||
| Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Verrica Pharmaceuticals | Formerly VC-backed | West Chester, PA | ||||
| Dermata | Formerly VC-backed | San Diego, CA | ||||
| Sol-Gel Technologies | Formerly PE-Backed | Ness Ziona, Israel |
Botanix Pharmaceuticals Patents
Botanix Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021904095-A0 | Cbd cannabinoids and cbd cannabinoid analogues | Inactive | 16-Dec-2021 | ||
| AU-2021901322-A0 | Cbd cannabinoids and cbd cannabinoid analogues | Inactive | 04-May-2021 | ||
| AU-2020904816-A0 | Cbd cannabinoids and cbd cannabinoid analogues | Inactive | 23-Dec-2020 | ||
| AU-2020903438-A0 | Antibacterial treatment using a cannabinoid and an active agent | Inactive | 24-Sep-2020 | ||
| AU-2019904935-A0 | Cannabinoids and cannabinoid analogues with antimicrobial activity | Inactive | 24-Dec-2019 |
Botanix Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Botanix Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Botanix Pharmaceuticals Investments & Acquisitions (2)
Botanix Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Brickell Biotech (Sofpironium Bromide Gel) for . The deal was made on 04-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Brickell Biotech (Sofpironium Bromide Gel) | 04-May-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Bone Medical | 27-Jun-2016 | Merger/Acquisition | Pharmaceuticals |
Botanix Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Botanix Pharmaceuticals FAQs
-
When was Botanix Pharmaceuticals founded?
Botanix Pharmaceuticals was founded in 1984.
-
Where is Botanix Pharmaceuticals headquartered?
Botanix Pharmaceuticals is headquartered in West Perth, Australia.
-
What is the size of Botanix Pharmaceuticals?
Botanix Pharmaceuticals has 2 total employees.
-
What industry is Botanix Pharmaceuticals in?
Botanix Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Botanix Pharmaceuticals a private or public company?
Botanix Pharmaceuticals is a Public company.
-
What is Botanix Pharmaceuticals’s stock symbol?
The ticker symbol for Botanix Pharmaceuticals is BOT.
-
What is the current stock price of Botanix Pharmaceuticals?
As of 16-May-2025 the stock price of Botanix Pharmaceuticals is $0.25.
-
What is the current market cap of Botanix Pharmaceuticals?
The current market capitalization of Botanix Pharmaceuticals is $482M.
-
Who are Botanix Pharmaceuticals’s competitors?
Clinuvel Pharmaceuticals, Rigel Pharmaceuticals, Verrica Pharmaceuticals, Dermata, and Sol-Gel Technologies are some of the 48 competitors of Botanix Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
